Neurology Central

Advances in nanomedicine for the treatment of Alzheimer’s and Parkinson’s diseases


Alzheimer‘s disease and Parkinson’s disease are the most common neurodegenerative diseases worldwide. Despite all the efforts made by the scientific community, current available treatments have limited effectiveness, without halting the progression of the disease. That is why, new molecules such as growth factors, antioxidants and metal chelators have been raised as new therapeutical approaches. However, these molecules have difficulties to cross the blood–brain barrier limiting its therapeutic effect.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.